drugset / Trial / NCT02644694

PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy

NCT02644694 ↗

Phase 1 Completed 10 enrolled Eyegate Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of dexamethasone phosphate ophthalmic solution delivered via the EyeGate® II Drug Delivery System (EGDS) in patients undergoing vitrectomy for macular hole repair or epiretinal membrane peeling

Timeline

Start
2016-03
Primary completion
2016-10
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 40 mg/ml —

Indications